| 1431 |
National Cancer Institute |
Html |
en |
Prostate Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. |
| cancer risk factors | 0.382888 |
| cancer treatment | 0.345379 |
| cancer prevention trials | 0.393424 |
| prostate cancer prevention | 0.528023 |
| cancer protective factor | 0.370188 |
| prostate gland | 0.401353 |
| Prostate Cancer Events | 0.438643 |
| protective factors | 0.37428 |
| Cancer Information Service | 0.363767 |
| following PDQ summaries | 0.363098 |
| PDQ cancer information | 0.439164 |
| advanced prostate cancer | 0.435515 |
| high-grade prostate cancer | 0.447263 |
| Clinical Trials section | 0.34275 |
| prevention clinical trials | 0.365763 |
| male sex | 0.35549 |
| white men | 0.343088 |
| men | 0.418793 |
| Prevention Editorial Board | 0.367822 |
| treatment clinical trials | 0.342421 |
| National Cancer Institute | 0.410797 |
| clinical trials | 0.465084 |
| folic acid | 0.367544 |
|
| cancer information summary | 0.404534 |
| fewer prostate cancers | 0.434955 |
| Vitamin E Cancer | 0.36527 |
| new treatment | 0.346999 |
| localized prostate cancer | 0.435368 |
| breast cancer prevention | 0.361722 |
| Cancer Prevention Trial | 0.41435 |
| prostate cancer increases | 0.444676 |
| prostate cancer risk | 0.48237 |
| cancer patients | 0.343751 |
| Cancer Care page | 0.358977 |
| cancer risk factor | 0.385548 |
| NCI’s PDQ | 0.343309 |
| normal prostate growth | 0.414243 |
| PDQ summary | 0.356651 |
| aggressive prostate cancers | 0.429295 |
| NCI PDQ cancer | 0.383175 |
| prostate cancer | 0.982122 |
| bigger prostate | 0.40149 |
| cancer clinical trials | 0.368698 |
| risk factors | 0.422068 |
| cancer information summaries | 0.367063 |
| comprehensive cancer information | 0.367142 |
|
CLICK HERE |
| 1587 |
National Cancer Institute |
Html |
en |
Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version |
Treatment of children with rhabdomyosarcoma often includes chemotherapy, radiation therapy, and surgery. Learn about the signs, tests to diagnose, survival, treatment, and clinical trials for children with rhabdomyosarcoma in this expert-reviewed summary. |
| cancer treatment | 0.508808 |
| alveolar tumor | 0.397789 |
| tissue | 0.446976 |
| body | 0.557677 |
| type | 0.525643 |
| chemotherapy | 0.500597 |
| PDQ cancer information | 0.443489 |
| childhood rhabdomyosarcoma | 0.648755 |
| stereotaxic radiation therapy | 0.400999 |
| embryonal tumor | 0.43303 |
| clinical trials | 0.703451 |
| rhabdomyosarcoma | 0.676649 |
| nearby lymph nodes | 0.746635 |
| cancer information summary | 0.418411 |
| rhabdomyosarcoma cells | 0.404898 |
| clinical trial | 0.53997 |
| sentinel lymph node | 0.434722 |
| malignant tumor cells | 0.470546 |
| body radiation therapy | 0.454423 |
| lymph nodes | 0.791456 |
| radiation therapy machine | 0.400658 |
| radiation therapy | 0.98278 |
| beam radiation therapy | 0.399186 |
| soft tissue sarcoma | 0.440069 |
|
| treatment | 0.729346 |
| wide local excision | 0.482565 |
| cancer cells | 0.726714 |
| Conformal radiation therapy | 0.416835 |
| treatment clinical trials | 0.409517 |
| stereotactic body radiation | 0.441552 |
| National Cancer Institute | 0.429355 |
| spinal cord | 0.406531 |
| metastatic rhabdomyosarcoma | 0.428908 |
| effects cancer treatment | 0.408271 |
| new treatment | 0.425898 |
| Intensity-modulated radiation therapy | 0.401599 |
| external-beam radiation therapy | 0.401022 |
| external radiation therapy | 0.507659 |
| primary tumor | 0.410338 |
| metastatic tumor | 0.420784 |
| Childhood Rhabdomyosarcoma Treatment | 0.412835 |
| bone marrow | 0.399523 |
| cancer clinical trials | 0.406325 |
| interstitial radiation therapy | 0.400167 |
| tumor | 0.799626 |
| recurrent rhabdomyosarcoma | 0.413207 |
| internal radiation therapy | 0.435661 |
| cancer | 0.935623 |
|
CLICK HERE |
| 1608 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Screening (PDQ®)–Patient Version |
There is no standard or routine screening test for stomach (gastric) cancer. Stomach (gastric) cancer is not common in the U.S. Learn about tests that have been studied to detect or screen for stomach cancer in this expert-reviewed summary. |
| PDQ Screening | 0.53696 |
| Serum pepsinogen levels | 0.476069 |
| cancer treatment | 0.489595 |
| better food storage | 0.483291 |
| cancer screening methods | 0.571194 |
| United States | 0.52237 |
| ongoing clinical trials | 0.488517 |
| screening tests | 0.527906 |
| silver-white metallic compound | 0.475608 |
| following PDQ summaries | 0.550231 |
| Cancer Information Service | 0.528818 |
| PDQ cancer information | 0.69988 |
| Prevention Editorial Board | 0.538784 |
| treatment clinical trials | 0.487954 |
| National Cancer Institute | 0.62168 |
| clinical trials | 0.622347 |
| PDQ documents | 0.494877 |
| test result | 0.484679 |
| cancer information summary | 0.615581 |
| cancer doctors | 0.478532 |
| clinical trial | 0.495039 |
| new treatment | 0.490527 |
| breast cancer prevention | 0.511108 |
|
| test results | 0.482671 |
| risk factors | 0.481306 |
| Cancer screening trials | 0.577316 |
| false-positive test result | 0.478411 |
| cancer patients | 0.482925 |
| Cancer Care page | 0.515504 |
| PDQ database | 0.499197 |
| latest published information | 0.490927 |
| PDQ® Screening | 0.477124 |
| NCI’s PDQ | 0.504099 |
| risk factor | 0.478731 |
| PDQ summary | 0.519732 |
| cancer symptoms | 0.504928 |
| NCI PDQ cancer | 0.579122 |
| certain risk factors | 0.477251 |
| lower salt intake | 0.475762 |
| tests | 0.5444 |
| stomach cancer | 0.956427 |
| cancer information summaries | 0.536975 |
| comprehensive cancer information | 0.53624 |
| Upper endoscopy | 0.478371 |
| stomach cancer screening | 0.661237 |
|
CLICK HERE |
| 1636 |
National Cancer Institute |
Html |
en |
Cartilage (Bovine and Shark) (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| cancer treatment | 0.483107 |
| human cancer cells | 0.399726 |
| cartilage treatment | 0.54785 |
| shark cartilage | 0.911115 |
| PDQ cancer information | 0.489648 |
| Cancer Complementary | 0.397259 |
| lung cancer | 0.396037 |
| new blood vessels | 0.529873 |
| blood vessel growth | 0.688109 |
| clinical trials | 0.661965 |
| testing bovine cartilage | 0.553086 |
| powdered cartilage products | 0.528871 |
| bovine cartilage | 0.754583 |
| cancer information summary | 0.450971 |
| clinical trial | 0.545778 |
| patients | 0.414137 |
| randomized clinical trial | 0.405563 |
| NCI PDQ cancer | 0.409125 |
| cancer information database | 0.395004 |
| liquid shark cartilage | 0.530016 |
| liquid cartilage products | 0.569642 |
| powdered shark cartilage | 0.613657 |
| cancer information | 0.501779 |
| breast cancer cells | 0.394321 |
|
| shark cartilage products | 0.633195 |
| laboratory study | 0.408409 |
| cartilage products | 0.782377 |
| Complementary Therapies Editorial | 0.405419 |
| cancer cells | 0.530307 |
| Cancer Information Service | 0.450397 |
| preclinical studies | 0.47111 |
| cartilage product AE–941/Neovastat | 0.510074 |
| dietary supplements | 0.394341 |
| National Cancer Institute | 0.540172 |
| studies | 0.47228 |
| alternative medicine | 0.440784 |
| pancreatic cancer cells | 0.3965 |
| human cartilage | 0.495387 |
| PDQ Cartilage | 0.50056 |
| shark cartilage product | 0.665863 |
| cartilage | 0.96677 |
| animal studies | 0.448189 |
| standard cancer treatment | 0.405448 |
| alternative therapies | 0.399716 |
| cancer information summaries | 0.395389 |
| powdered cartilage | 0.59313 |
| bovine cartilage product | 0.523261 |
| cancer | 0.811115 |
|
CLICK HERE |
| 1983 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles. |
| meduloblastoma wnt | 0.448042 |
| primitive neuroectodermal tumors | 0.463972 |
| Kool M | 0.408951 |
| tumores wnt | 0.418547 |
| prognostic factors | 0.423834 |
| germline mutations | 0.4087 |
| with medulloblastoma harboring | 0.411601 |
| with medulloblastoma receiving | 0.411471 |
| early childhood medulloblastoma | 0.42493 |
| childhood medulloblastoma | 0.434401 |
| meduloblastomas shh | 0.413706 |
| Rutkowski S | 0.412968 |
| Clin Pract Oncol | 0.409953 |
| with carboplatin | 0.411606 |
| with localized medulloblastoma | 0.410611 |
| Natl Cancer Inst | 0.412552 |
| vÃa wnt | 0.411172 |
| with retinoblastoma during | 0.417144 |
| Medulloblastoma with extensive | 0.410624 |
| Acta Neuropathol | 0.421932 |
| Boyett JM | 0.420388 |
| Children's Cancer | 0.444511 |
| Lancet Oncol | 0.408704 |
| medulloblastoma subtypes with | 0.411732 |
| subtipo shh | 0.409562 |
|
| meduloblastomas wnt | 0.413294 |
| Remke M | 0.416131 |
| tumores shh | 0.419097 |
| Neuro Oncol | 0.413263 |
| Pediatr Blood Cancer | 0.465506 |
| Childrens Cancer Group | 0.412973 |
| neuroectodermal tumors treated | 0.41729 |
| with medulloblastoma | 0.429537 |
| Med Genet | 0.409674 |
| Clin Oncol | 0.618048 |
| sistema nervioso central | 0.455844 |
| with supratentorial primitive | 0.416554 |
| pediatric medulloblastoma | 0.410979 |
| Children's Cancer Group | 0.43162 |
| von hoff k | 0.413579 |
| tumors treated with | 0.41728 |
| término tumor | 0.409479 |
| tumores embrionarios | 0.947028 |
| Kingdom Children Cancer | 0.420872 |
| vÃa shh | 0.424313 |
| children's oncology group | 0.440874 |
| Children's Cancer Study | 0.422483 |
| molecular subgroups | 0.410404 |
| Cancer Study Group | 0.41491 |
|
CLICK HERE |
| 3453 |
National Cancer Institute |
Html |
es |
Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre la preparación necesaria por parte de los proveedores de atención de la salud, los pacientes y sus familias para la transición a la atención del cáncer avanzado en la etapa final de la vida. |
| health care spending | 0.331274 |
| Zimmermann C | 0.347816 |
| Burman D | 0.32527 |
| posibles factores | 0.333049 |
| Ewer MS | 0.322761 |
| cancer care near | 0.391306 |
| creciente número | 0.323261 |
| Sin embargo | 0.941022 |
| American Cancer Society | 0.434589 |
| etapa efv | 0.333862 |
| Health Care Brief | 0.329424 |
| fase ii | 0.322051 |
| Swami N | 0.348223 |
| care providers | 0.323463 |
| intensive care unit | 0.365314 |
| Cancer Care Outcomes | 0.349727 |
| coping with cancer | 0.340049 |
| quimioterapia paliativa | 0.367064 |
| cancer care | 0.411213 |
| Early palliative care | 0.33009 |
| Landrum MB | 0.323564 |
| Dartmouth Institute | 0.324797 |
| Estados Unidos | 0.323783 |
| Support Care | 0.43154 |
| mayores gastos | 0.34678 |
|
| Med Care | 0.326126 |
| patients with | 0.439314 |
| end-of-life care | 0.465368 |
| good death | 0.325189 |
| Care Cancer | 0.418414 |
| Cancer Facts | 0.334548 |
| fase i | 0.325785 |
| palliative care | 0.349857 |
| cardiac arrest | 0.325245 |
| Dartmouth Atlas | 0.325161 |
| ill patients with | 0.328355 |
| cardiopulmonary resuscitation | 0.351378 |
| medical intensive care | 0.329231 |
| care intensity | 0.323054 |
| beneficiaries dying with | 0.321915 |
| Clinical Practice | 0.32872 |
| forma favorable calidad | 0.324109 |
| alta calidad | 0.387852 |
| Health Policy | 0.327199 |
| health care | 0.342416 |
| Intern Med | 0.355877 |
| Clin Oncol | 0.402042 |
| Arch Intern Med | 0.354168 |
| respiración mecánica | 0.42963 |
|
CLICK HERE |
| 3456 |
National Cancer Institute |
Html |
es |
Acupuntura (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre la acupuntura como tratamiento para las personas con cáncer o trastornos relacionados con esta enfermedad. |
| acupuntura forma | 0.644774 |
| Centro Nacional | 0.425173 |
| causa reacciones | 0.422733 |
| New Hampshire Avenue | 0.41766 |
| acupuntos correctos | 0.426568 |
| causa hinchazón | 0.417784 |
| Drug Administration | 0.410869 |
| neuropatÃa periférica | 0.548649 |
| NCI Best Case | 0.428652 |
| datos bibliográficos pubmed | 0.418907 |
| largo plazo | 0.414083 |
| National Cancer Institute | 0.420958 |
| siglo xviii | 0.41833 |
| siguientes riesgos | 0.413128 |
| PDQ Acupuntura | 0.568448 |
| acupuntura ayuda | 0.53948 |
| Instituto Nacional | 0.496395 |
| numerosos informes | 0.41497 |
| National Certification Commission | 0.424144 |
| Salud Complementaria | 0.436282 |
| Visuals Online | 0.412814 |
|
| náuseas matutinas | 0.436773 |
| mamaEl linfedema | 0.418357 |
| complementarias revisa | 0.41658 |
| sistema nervioso central | 0.511178 |
| Physician Data Query | 0.473664 |
| Medicina Oriental | 0.41709 |
| Estados Unidos | 0.901304 |
| Comisión Nacional | 0.410413 |
| libre uso | 0.418723 |
| Oriental Medicine | 0.412484 |
| distintos resultados | 0.413109 |
| cabo estudios | 0.47129 |
| piel agujas | 0.436066 |
| página manejo | 0.412054 |
| ¿El tratamiento | 0.424697 |
| ¿Los beneficios | 0.410887 |
| juntos cam | 0.410417 |
| qi causa dolor | 0.459263 |
| Series Program | 0.410794 |
| medicina complementaria | 0.788071 |
| Institutos Nacionales | 0.521236 |
|
CLICK HERE |
| 3519 |
National Cancer Institute |
Html |
en |
Research Team Members |
Information about the different types of experts involved in designing and running a clinical trial. |
| treatment | 0.240173 |
| Typical team members | 0.477277 |
| data management | 0.339957 |
| records | 0.222317 |
| Staff physician | 0.322575 |
| concept | 0.2227 |
| aspects | 0.224933 |
| Institutional Review Board | 0.455886 |
| study monitoring | 0.329306 |
| Treats patients | 0.324814 |
| skills | 0.22687 |
| presentation | 0.223824 |
| Supervises data collection | 0.479065 |
| responsibilities | 0.228481 |
| recruitment | 0.225467 |
| course | 0.246736 |
| health care providers | 0.443729 |
| Works | 0.240321 |
| audits | 0.222243 |
|
| research nurse | 0.569926 |
| final data analysis | 0.435286 |
| clinical trial | 0.945844 |
| Provides data | 0.334954 |
| approval | 0.227398 |
| different sites | 0.354975 |
| monitoring agencies | 0.324055 |
| Assesses | 0.227864 |
| Data manager | 0.339195 |
| different types | 0.351452 |
| Communicates | 0.231534 |
| principal investigator | 0.901171 |
| person | 0.339796 |
| quality assurance | 0.332626 |
| Educates staff | 0.334468 |
| IRB | 0.235474 |
| Designing | 0.224461 |
| informed consent process | 0.715664 |
| experts | 0.226806 |
|
CLICK HERE |
| 3963 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de orofaringe (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe. |
| tratamiento.Ciertas formas | 0.441948 |
| Neck Cancer | 0.50872 |
| siguientes procedimientos | 0.637903 |
| corporal estereotáctica | 0.73941 |
| estadio iv | 0.619806 |
| hormona tiroidea | 0.524054 |
| siguientes elementos | 0.501559 |
| estadio ii | 0.502031 |
| rayos x | 0.464154 |
| pequeñas marcas | 0.437304 |
| estadio ivc | 0.501067 |
| enlace drugs approved | 0.605888 |
| orofaringe ayuda | 0.523898 |
| aguja fina.Se | 0.467807 |
| PDQ Consumo | 0.531679 |
|
| estadio iva | 0.502486 |
| vÃas respiratorias | 0.466653 |
| cirujano manipula herramientas | 0.481463 |
| pequeñas mejora | 0.437701 |
| National Cancer Institute | 0.433607 |
| siguientes riesgos | 0.427789 |
| Instituto Nacional | 0.463265 |
| malla ayuda | 0.439384 |
| PDQ Tratamiento | 0.485984 |
| Physician Data Query | 0.531575 |
| radioterapia hiperfraccionada | 0.624557 |
| ganglio linfático mide | 0.948968 |
| cáncer.ampliar radioterapia | 0.563245 |
| distinta intensidad | 0.445146 |
| siguientes sumarios | 0.538888 |
|
CLICK HERE |
| 4394 |
National Cancer Institute |
Html |
null |
Blue Ribbon Panel Working Groups |
Seven working groups comprised of leading experts from the cancer community have been charged with developing recommendations for the Cancer Moonshot Initiative. |
|
|
CLICK HERE |